Nirmidas Biotech Finds $2M
San Francisco-based Nirmidas Biotech, a company developing technology for detecting disease biomarkers, has raised $2m in a seed funding round. The company--which is based on research out of Stanford--said the funding came from the Stanford StartX fund, as well as other un-named venture investors. The company says it is developing fluorescence enhancing technology for gold slides, which it calls pGOLD.
posted on Tuesday, August 19, 2014 (Link to more information)
Related companies:
Nirmidas Biotech
Related stories:
> Aduro BioTech Finds $55M
> ACT Biotech Gets $12M For Cancer Drugs
> Microvi Biotech Gains Financing
> Facet Biotech Acquired By Abbott
> Quark Biotech Files For IPO
silicontap.com Home